Bexarotene safe treatment for early-stage CTCL

June 1, 2001

Washington - Bexarotene gel appears to be an effective and well-tolerated monotherapy when used as first-line treatment for early-stage cutaneous T-cell lymphoma, Madeleine Duvic, M.D., reported at the annual meeting of the American Academy of Dermatology.

Related Content:

News | Anti-Aging